Circassia Itching To Transform Allergy Sector
Executive Summary
U.K. biotech Circassia has the first potential cat allergy vaccine to reach advanced clinical studies in Europe and the U.S., funded by a large round of VC financing completed in 2011. Its allergen-free technology could revolutionize the treatment of allergies.
You may also be interested in...
In Short Order, Merck And Stallergenes File BLAs For New Allergy Immunotherapies
Both Merck and French biotech Stallergenes have filed BLAs with FDA for approval of their respective grass allergy immunotherapies.
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
Allergy-Focused Circassia Raises £60m, Led by Imperial Innovations
Funding round is Europe's fifth-largest in over a decade, underscoring investor confidence in Circassia's T-cell vaccine technology.